← Back to Search

Antiviral

Nirmatrelvir/ritonavir for Bioavailability

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination (PE), laboratory tests, vital signs and standard 12 lead ECGs.
Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours
Awards & highlights

Study Summary

This trial will test how well different versions of a drug are absorbed by the body.

Eligible Conditions
  • Bioavailability
  • Healthy Subjects

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under curve from time zero to 72 hours post dose
Peak plasma concentration (Cmax)
Secondary outcome measures
Number of Participants With Clinically Notable Abnormality in physical examination
Number of Participants With Clinically Notable Changes in Clinical laboratory
Number of Participants With Clinically Notable Vital Signs
+2 more

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Group I: Treatment E: Nirmatrelvir/ ritonavirExperimental Treatment1 Intervention
Nirmatrelvir/ ritonavir test tablets
Group II: Treatment D: Nirmatrelvir/ ritonavirExperimental Treatment1 Intervention
Nirmatrelvir/ ritonavir test tablets
Group III: Treatment C: Nirmatrelvir/ ritonavirExperimental Treatment1 Intervention
Nirmatrelvir/ ritonavir test tablets
Group IV: Treatment B: Nirmatrelvir/ ritonavirExperimental Treatment1 Intervention
Nirmatrelvir/ ritonavir test tablets
Group V: Treatment A: Nirmatrelvir/ritonavirActive Control1 Intervention
Nirmatrelvir and ritonavir tablets
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nirmatrelvir/ritonavir
2023
Completed Phase 1
~40
Nirmatrelvir/ ritonavir
2022
Completed Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

PfizerLead Sponsor
4,558 Previous Clinical Trials
10,907,625 Total Patients Enrolled
4 Trials studying Bioavailability
62 Patients Enrolled for Bioavailability
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,469 Previous Clinical Trials
8,089,106 Total Patients Enrolled
4 Trials studying Bioavailability
62 Patients Enrolled for Bioavailability

Frequently Asked Questions

~6 spots leftby Mar 2025